Open collaboration with academia, biotech and pharma
- R&D R&D at the heart of our mission to develop global medicines for treatment of incurable diseases.
- Pipeline Specalized in antibody research for treatment of autoimmune disease, dry eye diseases, and immuno-oncology drugs.
- People We strive to make healthier, happier and better today.
- Compliance and Ethics We act with high ethics.
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s DiseaseIn Detail
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye DiseaseIn Detail
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business UpdateIn Detail